.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,973,038

« Back to Dashboard

Details for Patent: 7,973,038

Title:Modulators of ATP-binding cassette transporters
Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Inventor(s): Hadida Ruah; Sara S. (LaJolla, CA), Hamilton; Matthew (New Jersey, CA), Miller; Mark T. (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Bear; Brian Richard (Oceanside, CA), McCartney; Jason (Cardiff by the Sea, CA), Zhou; Jinglan (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Filing Date:Apr 28, 2010
Application Number:12/768,894
Claims:1. A method of modulating CFTR transporter activity comprising the step of contacting said ABC transporter with a compound of formula (I): ##STR00530## wherein: each R.sub.1 is an optionally substituted C.sub.1-6 aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C.sub.3-10 cycloaliphatic, an optionally substituted 3 to 10 membered heterocycloaliphatic, carboxy, amido, amino, halo, or hydroxy, provided that at least one R.sub.1 is an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl attached to the 5- or 6-position of the pyridyl ring; each R.sub.2 is hydrogen, an optionally substituted C.sub.1-6 aliphatic, an optionally substituted C.sub.3-6 cycloaliphatic, an optionally substituted phenyl, or an optionally substituted heteroaryl; each R.sub.3 and R'.sub.3 together with the carbon atom to which they are attached form an optionally substituted C.sub.3-7 cycloaliphatic or an optionally substituted heterocycloaliphatic; each R.sub.4 is an optionally substituted aryl or an optionally substituted heteroaryl; and each n is 1-4.

2. A method of treating or lessening the severity of a disease in a patient, wherein said disease is selected from cystic fibrosis, hereditary emphysema, or COPD, said method comprising the step of administering to said patient an effective amount of a compound of formula I: ##STR00531## or a pharmaceutically acceptable salt thereof, wherein: Each R.sub.1 is an optionally substituted C.sub.1-6 aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C.sub.3-10 cycloaliphatic, an optionally substituted 3 to 10 membered heterocycloaliphatic, carboxy, amido, amino, halo, or hydroxy, provided that at least one R.sub.1 is an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl attached to the 5- or 6- position of the pyridyl ring; Each R.sub.2 is hydrogen, an optionally substituted C.sub.1-6 aliphatic, an optionally substituted C.sub.3-6 cycloaliphatic, an optionally substituted phenyl, or an optionally substituted heteroaryl; Each R.sub.3 and R'.sub.3 together with the carbon atom to which they are attached form an optionally substituted C.sub.3-7 cycloaliphatic or an optionally substituted heterocycloaliphatic; Each R.sub.4 is an optionally substituted aryl or an optionally substituted heteroaryl; and Each n is 1, 2, 3 or 4.

3. The method according to claim 2, wherein one R.sub.1 that is attached to 5- or 6-position of the pyridyl ring is aryl or heteroaryl, each optionally substituted with 1, 2, or 3 of R.sup.D; wherein R.sup.D is --Z.sup.DR.sub.9; wherein each Z.sup.D is independently a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein up to two carbon units of Z.sup.D are optionally and independently replaced by --CO--, --CS--, --CONR.sup.E--, --CONR.sup.ENR.sup.E--, --CO.sub.2--, --OCO--, --NR.sup.ECO.sub.2--, --O--, --NR.sup.ECONR.sup.E--, --OCONR.sup.E--, --NR.sup.ENR.sup.E--, --NR.sup.ECO--, --S--, --SO--, --SO.sub.2--, --NR.sup.E--, --SO.sub.2NR.sup.E--, --NR.sup.ESO.sub.2--, or --NR.sup.ESO.sub.2NR.sup.E--; each R.sub.9 is independently R.sup.E, halo, --OH, --NH.sub.2, --NO.sub.2, --CN, --CF.sub.3, or --OCF.sub.3; and each R.sup.E is independently hydrogen, an optionally substituted C.sub.1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.

4. The method according to claim 3, wherein the one R.sub.1 attached to the 5- or 6-position of the pyridyl ring is phenyl optionally substituted with 1, 2, or 3 of R.sup.D.

5. The method according to claim 3, wherein the one R.sub.1 attached to the 5- or 6-position of the pyridyl ring is heteroaryl optionally substituted with 1, 2, or 3 of R.sup.D.

6. The method according to claim 3, wherein one R.sub.1 attached to the 5- or 6-position of the pyridyl ring is a 5 or 6 membered heteroaryl having 1, 2, or 3 heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with 1 of R.sup.D, wherein R.sup.D is --Z.sup.DR.sub.9; each Z.sup.D is independently a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein up to two carbon units of Z.sup.D are optionally and independently replaced by --O--, --NHC(O)--, --C(O)NR.sup.E--, --SO.sub.2--, --NHSO.sub.2--, --NHC(O)--, --NR.sup.ESO.sub.2--, --SO.sub.2NH--, --SO.sub.2NR.sup.E--, --NH--, or --C(O)O--.

7. The method according to claim 6, wherein one carbon unit of Z.sup.D is replaced by --O--, --NHC(O)--, --C(O)NR.sup.E--, --SO.sub.2--, --NHSO.sub.2--, --NHC(O)--, --SO--, --NR.sup.ESO.sub.2--, --SO.sub.2NH--, --SO.sub.2NR.sup.E--, --NH--, or --C(O)O--.

8. The method according to claim 3, wherein R.sub.9 is independently an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl, H, or halo.

9. The method according to claim 2, wherein one R.sub.1 that is attached to the 5- or 6-position of the pyridyl ring is cycloaliphatic or heterocycloaliphatic, each optionally substituted with 1, 2, or 3 of R.sup.D.

10. The method according to claim 9, wherein one R.sub.1 that is attached to the 5- or 6-position of the pyridyl ring is an optionally substituted C.sub.3-C.sub.8 cycloalkyl or an optionally substituted C.sub.3-C.sub.8 cycloalkenyl.

11. The method according to claim 2, wherein the one R.sub.1 attached to the 5- or 6-position of the pyridyl ring is selected from the group consisting of ##STR00532## ##STR00533## ##STR00534## ##STR00535## ##STR00536## ##STR00537## ##STR00538## ##STR00539## ##STR00540## ##STR00541##

12. The method according to claim 2, wherein R.sub.2 is hydrogen.

13. The method according to claim 2, wherein R.sub.3 and R'.sub.3 together with the carbon atom to which they are attached form an unsubstituted C.sub.3-7 cycloaliphatic or an unsubstituted heterocycloaliphatic.

14. The method according to claim 13, wherein R.sub.3 and R'.sub.3 together with the carbon atom to which they are attached form an unsubstituted cyclopropyl, an unsubstituted cyclopentyl, or an unsubstituted cyclohexyl.

15. The method according to claim 2, wherein R.sub.4 is an aryl or heteroaryl optionally substituted with 1, 2, or 3 of --Z.sup.CR.sub.8, wherein each Z.sup.C is independently a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein up to two carbon units of Z.sup.C are optionally and independently replaced by --CO--, --CS--, --CONR.sup.C--, --CONR.sup.CNR.sup.C--, --CO.sub.2--, --OCO---, --NR.sup.CCO.sub.2--, --O--, --NR.sup.CCONR.sup.C--, --OCONR.sup.C--, --NR.sup.CNR.sup.C--, --NR.sup.CCO--, --S--, --SO--, --SO.sub.2--, --NR.sup.C--, --SO.sub.2NR.sup.C--, --NR.sup.CSO.sub.2--, or --NR.sup.CSO.sub.2NR.sup.C--; each R.sub.8 is independently R.sup.C, halo, --OH, --NH.sub.2, --NO.sub.2, --CN, or --OCF.sub.3; and each R.sup.C is independently an optionally substituted C.sub.1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.

16. The method according to claim 15, wherein R.sub.4 is an aryl optionally substituted with 1, 2, or 3 of --Z.sup.CR.sub.8.

17. The method according to claim 16, wherein R.sub.4 is an optionally substituted phenyl.

18. The method according to claim 15, wherein R.sub.4 is a heteroaryl optionally substituted with 1, 2, or 3 of --Z.sup.C.sub.8.

19. The method according to claim 15, wherein R.sub.4 is one selected from ##STR00542## ##STR00543##

20. The method according to claim 2, wherein said compound has formula (IV): ##STR00544## or a pharmaceutically acceptable salt thereof, wherein R.sup.D is --Z.sup.DR.sub.9, wherein each Z.sup.D is independently a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein up to two carbon units of Z.sup.D are optionally and independently replaced by --CO--, --CS--, --CONR.sup.E--, --CONR.sup.ENR.sup.E--, --CO.sub.2--, --OCO--, --NR.sup.ECO.sub.2--, --O--, --NR.sup.ECONR.sup.E--, --OCONR.sup.E--, --NR.sup.ENR.sup.E--, --NR.sup.ECO--, --S--, --SO--, --SO.sub.2--, --NR.sup.E--, --SO.sub.2NR.sup.E--, --NR.sup.ESO.sub.2--, or --NR.sup.ESO.sub.2NR.sup.E--; R.sub.9 is independently R.sup.E, halo, --OH, --NH.sub.2, --NO.sub.2, --CN, --CF.sub.3, or --OCF.sub.3; Each R.sup.E is independently hydrogen, an optionally substituted C.sub.1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl; R.sub.2 is C.sub.1-4 aliphatic, C.sub.3-6 cycloaliphatic, phenyl, or heteroaryl, each of which is optionally substituted, or R.sub.2 is hydrogen; R.sub.3 and R'.sub.3 together with the carbon atom to which they are attached form a C.sub.3-7 cycloaliphatic or a C.sub.3-7 heterocycloaliphatic, each of which is optionally substituted with 1, 2, or 3 of --Z.sup.BR.sub.7, wherein each Z.sup.B is independently a bond, or an optionally substituted branched or straight C.sub.1-4 aliphatic chain wherein up to two carbon units of Z.sup.B are optionally and independently replaced by --CO--, --CS--, --CONR.sup.B--, --CONR.sup.BNR.sup.B--, --CO.sub.2--, --OCO--, --NR.sup.BCO.sub.2--, --O--, --NR.sup.BCONR.sup.B--, --OCONR.sup.B--, --NR.sup.BNR.sup.B--, --NR.sup.BCO--, --S--, --SO--, --SO.sub.2--, --NR.sup.B--, --SO.sub.2NR.sup.B--, --NR.sup.BSO.sub.2--, or --NR.sup.BSO.sub.2NR.sup.B--; Each R.sub.7 is independently R.sup.B, halo, --OH, --NH.sub.2, --NO.sub.2, --CN, --CF.sub.3, or --OCF.sub.3; Each R.sup.B is independently hydrogen, an optionally substituted C.sub.1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl; Each R.sub.4 is an aryl or heteroaryl, each of which is optionally substituted with 1, 2, or 3 of --Z.sup.CR.sub.8, wherein each Z.sup.C is independently a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein up to two carbon units of Z.sup.C are optionally and independently replaced by --CO--, --CS--, --CONR.sup.C--, --CONR.sup.CNR.sup.C--, --CO.sub.2--, --OCO--, --NR.sup.CCO.sub.2-, --O--, --NR.sup.CCONR.sup.C--, --OCONR.sup.C--, --NR.sup.CNR.sup.C--, --NR.sup.CCO--, --S--, --SO--, --SO.sub.2--, --NR.sup.C--, --SO.sub.2NR.sup.C--, --NR.sup.CSO.sub.2--, or --NR.sup.CSO.sub.2NR.sup.C--; Each R.sub.8 is independently R.sup.C, halo, --OH, --NH.sub.2, --NO.sub.2, --CN, --CF.sub.3, or --OCF.sub.3; and Each R.sup.C is independently an optionally substituted C.sub.1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.

21. The method according to claim 20, wherein said compound has formula V-A or formula V-B: ##STR00545## or a pharmaceutically acceptable salt thereof, wherein: T is an optionally substituted C.sub.1-2 aliphatic chain, wherein each of the carbon units is optionally and independently replaced by --CO--, --CS--, --COCO--, --SO.sub.2--, --B(OH)--, or --B(O(C.sub.1-6 alkyl))--; Each of R.sub.1' and R.sub.1'' is an optionally substituted C.sub.1-6 aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted 3 to 10 membered cycloaliphatic, an optionally substituted 3 to 10 membered heterocycloaliphatic, carboxy, amido, amino, halo, or hydroxy; R.sup.D1 is attached to carbon number 3'' or 4''; each R.sup.D1 and R.sup.D2 is --Z.sup.DR.sub.9, wherein each Z.sup.D is independently a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein up to two carbon units of Z.sup.D are optionally and independently replaced by --CO--, --CS--, --CONR.sup.E--, --CONR.sup.ENR.sup.E--, --CO.sub.2--, --OCO--, --NR.sup.ECO.sub.2--, --O--, --NR.sup.ECONR.sup.E--, --OCONR.sup.E--, --NR.sup.ENR.sup.E--, --NR.sup.ECO--, --S--, --SO--, --SO.sub.2--, --NR.sup.E--, --SO.sub.2NR.sup.E--, --NR.sup.ESO.sub.2--, or --NR.sup.ESO.sub.2NR.sup.E--; R.sub.9 is independently R.sup.E, halo, --OH, --NH.sub.2, --NO.sub.2, --CN, --CF.sub.3, or --OCF.sub.3; or R.sup.D1 and R.sup.D2, taken together with atoms to which they are attached, form a 3-8 membered saturated, partially unsaturated, or aromatic ring with up to 3 ring members independently selected from the group consisting of O, NH, NR.sup.E, and S; and each R.sup.E is independently hydrogen, an optionally substituted C.sub.1-8 aliphatic group, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.

22. The method according to claim 21, wherein up to two methylene units of T are independently and optionally replaced by --CO--, --CS--, --B(OH), or --B(O(C.sub.1-6 alkyl).

23. The method according to claim 21, wherein T is an optionally substituted chain selected from the group consisting of --CH.sub.2-- and --CH.sub.2CH.sub.2--.

24. The method according to claim 21, wherein T is optionally substituted by F, Cl, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, phenyl, naphthyl, --O--(C.sub.1-6 alkyl), --O--(C.sub.3-8 cycloalkyl), --O-phenyl, or C.sub.3-8 spiroaliphatic.

25. The method according to claim 21, wherein T is selected from the group consisting of --CH.sub.2--, --CH.sub.2CH.sub.2--, --CF.sub.2--, --C(CH.sub.3).sub.2--, --C(O)--, ##STR00546## --C(Phenyl).sub.2--, --B(OH)--, and --CH(OEt)-.

26. The method according to claim 25, wherein T is selected from the group consisting of --CH.sub.2--, --CF.sub.2--, and --C(CH.sub.3).sub.2--.

27. The method according to claim 21, wherein Z.sup.D is independently a bond or an optionally substituted branched or straight C.sub.1-6 aliphatic chain wherein one carbon unit of Z.sup.D is optionally replaced by --CO--, --SO--, --SO.sub.2--, --COO--, --OCO--, --CONR.sup.E--, --NR.sup.ECO--, NR.sup.ECO.sub.2--, --O--, --NR.sup.ESO.sub.2--, or --SO.sub.2NR.sup.E--.

28. The method according to claim 21, wherein R.sup.D1 is --Z.sup.DR.sub.9, wherein R.sub.9 is halo, --OH, --NH.sub.2, --CN, --CF.sub.3, --OCF.sub.3, or an optionally substituted group selected from the group consisting of C.sub.1-6 aliphatic, C.sub.3-8 cycloaliphatic, 3-8 membered heterocycloaliphatic, C.sub.6-10 aryl, and 5-10 membered heteroaryl.

29. The method according to claim 28, wherein R.sub.9 is F, Cl, --OH, --CN, --CF.sub.3, or --OCF.sub.3.

30. The method according to claim 28, wherein R.sub.9 is selected from the group consisting of C.sub.1-6 straight or branched alkyl or C.sub.2-6 straight or branched alkenyl; wherein said alkyl or alkenyl is optionally substituted by 1 or 2 substituents independently selected from the group consisting of R.sup.E, oxo, halo, --OH, --NR.sup.ER.sup.E, --OR.sup.E, --COOR.sup.E, and --CONR.sup.ER.sup.E.

31. The method according to claim 28, wherein R.sub.9 is C.sub.3-8 cycloaliphatic optionally substituted by 1 or 2 substituents independently selected from the group consisting of R.sup.E, oxo, halo, --OH, --NR.sup.ER.sup.E, --OR.sup.E, --COOR.sup.E, and --CONR.sup.ER.sup.E.

32. The method according to claim 31, wherein R.sub.9 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.

33. The method according to claim 28, wherein R.sup.9 is a 3-8 membered heterocyclic with 1 or 2 heteroatoms independently selected from the group consisting of O, NH, NR.sup.E, and S; wherein said heterocyclic is optionally substituted by 1 or 2 substituents independently selected from the group R.sup.E, oxo, halo, --OH, --NR.sup.ER.sup.E, --OR.sup.E, --COOR.sup.E, and --CONR.sup.ER.sup.E.

34. The method according to claim 33, wherein R.sup.9 is an optionally substituted 3-8 membered heterocyclic is ##STR00547##

35. The method according to claim 33, wherein R.sup.9 is optionally substituted by 1 or 2 substituents independently selected from the group consisting of oxo, F, Cl, methyl, ethyl, i-propyl, t-butyl, --CH.sub.2OH, --CH.sub.2CH.sub.2OH, --C(O)OH, --C(O)NH.sub.2, --CH.sub.2O(C.sub.1-6 alkyl), --CH.sub.2CH.sub.2O(C.sub.1-6 alkyl), and --C(O)(C.sub.1-6 alkyl).

36. The method according to claim 28, wherein R.sup.9 is 5-8 membered heteroaryl with 1 or two ring atom independently selected from the group consisting of O, S, and NR.sup.E; wherein said heteroaryl is optionally substituted by 1 or 2 substituents independently selected from the group R.sup.E, oxo, halo, --OH, --NR.sup.ER.sup.E, --OR.sup.E, --COOR.sup.E, and --CONR.sup.ER.sup.E.

37. The method according to claim 36, wherein R.sup.9 is ##STR00548##

38. The method according to claim 36, wherein R.sup.9 is optionally substituted by 1 or 2 substituents independently selected from the group consisting of F, Cl, methyl, ethyl, i-propyl, t-butyl, --CH.sub.2OH, --CH.sub.2CH.sub.2OH, --C(O)OH, --C(O)NH.sub.2, --CH.sub.2O(C.sub.1-6 alkyl), --CH.sub.2CH.sub.2O(C.sub.1-6 alkyl), and --C(O)(C.sub.1-6 alkyl).

39. The method according to claim 21, wherein R.sup.D1 and R.sup.D2, taken together with carbons to which they are attached, form an optionally substituted 3-8 membered saturated, partially unsaturated, or aromatic ring with 0-2 ring atoms independently selected from the group consisting of O, NH, NR.sup.E, and S.

40. The method according to claim 39, wherein R.sup.D1 and R.sup.D2, taken together with phenyl containing carbon atoms 3'' and 4'', is ##STR00549##

41. The method according to claim 39, wherein R.sup.D1 and R.sup.D2, taken together with phenyl containing carbon atoms 3'' and 4'', is optionally substituted by 1 or 2 substituents independently selected from the group consisting of R.sup.E, oxo, halo, --OH, --NR.sup.ER.sup.E, --OR.sub.E, --COOR.sup.E, and --CONR.sup.ER.sup.E.

42. The method according to claim 21, wherein R.sup.D2 is selected from the group consisting of H, C.sub.1-6 aliphatic, halo, --CN, --NH.sub.2, --CH.sub.2NH.sub.2, --OH, --O(C.sub.1-6 aliphatic), --CH.sub.2OH, --SO.sub.2(C.sub.1-6 aliphatic), --NH--SO.sub.2(C.sub.1-6 aliphatic), --C(O)O(C.sub.1-6 aliphatic), --C(O)OH, --NHC(O)(C.sub.1-6 aliphatic), --C(O)NH.sub.2, --C(O)NH(C.sub.1-6 aliphatic), and --C(O)N(C.sub.1-6 aliphatic).sub.2.

43. The method according to claim 21, wherein R.sub.1'' is hydrogen.

44. The method according to claim 21, wherein R.sub.1' and R.sub.1'' are both hydrogen.

45. The method according to claim 2, wherein the compound is selected from ##STR00550## ##STR00551## ##STR00552## ##STR00553## ##STR00554## ##STR00555## ##STR00556## ##STR00557## ##STR00558## ##STR00559## ##STR00560## ##STR00561## ##STR00562## ##STR00563## ##STR00564## ##STR00565## ##STR00566## ##STR00567## ##STR00568## ##STR00569## ##STR00570## ##STR00571## ##STR00572## ##STR00573## ##STR00574## ##STR00575## ##STR00576## ##STR00577## ##STR00578## ##STR00579## ##STR00580## ##STR00581## ##STR00582## ##STR00583## ##STR00584## ##STR00585## ##STR00586## ##STR00587## ##STR00588## ##STR00589## ##STR00590## ##STR00591## ##STR00592## ##STR00593## ##STR00594## ##STR00595## ##STR00596## ##STR00597## ##STR00598## ##STR00599## ##STR00600## ##STR00601## ##STR00602## ##STR00603## ##STR00604## ##STR00605## ##STR00606## ##STR00607## ##STR00608## ##STR00609## ##STR00610## ##STR00611## ##STR00612## ##STR00613## ##STR00614## ##STR00615## ##STR00616## ##STR00617## ##STR00618## ##STR00619## ##STR00620## ##STR00621## ##STR00622## ##STR00623## ##STR00624## ##STR00625## ##STR00626## ##STR00627## ##STR00628## ##STR00629## ##STR00630## ##STR00631## ##STR00632## ##STR00633## ##STR00634## ##STR00635## ##STR00636## ##STR00637##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc